METASTATIC CANCER

This study tests whether two common immunotherapy drugs, nivolumab and pembrolizumab, can be given less frequently than the current standard schedule for people with advanced cancers. Researchers will compare drug levels in the blood to see if extended dosing keeps the drugs effe…

This study tests a new drug called PC14586 (rezatapopt) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The goal is to see if the drug is safe and shrinks tumors. About 300 adults whose cancer has worsened after prior treatment will take the drug al…

This study tests a new immunotherapy for people with advanced HPV-related cancers (cervical, throat, anal, and others). Doctors take a patient's own immune cells, add a special receptor to help them find and attack HPV-infected cancer cells, and give them back. The goal is to shr…

This study tests whether adding the drug azeliragon to targeted radiation therapy can safely shrink brain tumors and keep them from growing back. About 46 adults with cancer that has spread to the brain will take part. The goal is to improve tumor control, not to cure the disease…

This study offers continued treatment with certain cancer drugs for people with advanced or metastatic cancer who are already benefiting from them in earlier studies. The main goal is to monitor long-term safety, including side effects. About 50 adults will take part, and the stu…

This study tests an experimental drug called ART0380, taken as a pill, for people with advanced or metastatic solid tumors (cancers that have spread). The goal is to find a safe dose and see if it works alone or with standard chemotherapies (gemcitabine or irinotecan). About 442 …

This study is testing an experimental radioactive drug called 177Lu-SN201 in people with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The drug is designed to deliver radiation directly to tumors. The main goals ar…

This study tests a new drug, IDRX-42, for people with advanced gastrointestinal stromal tumors (GIST) that have spread or cannot be removed by surgery. The goal is to see if the drug is safe and can shrink or control these tumors. About 278 adults who have already tried the stand…

This early-stage study tests whether using high-intensity focused ultrasound to destroy tumors from the inside can boost the effects of immunotherapy drugs (ipilimumab and nivolumab) in adults with advanced cancer that has stopped responding to standard treatments. The main goals…

This early-phase trial tests an experimental drug called ALTA2618 in about 110 adults whose advanced solid tumors (like breast or endometrial cancer) have a specific AKT1 E17K gene change. The main goal is to check the drug's safety and find the right dose. Participants must have…

This study tests a new drug, MGC026, in 250 adults with advanced solid tumors that have not responded to other treatments. The goal is to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants receive the drug by IV and are closely monitored f…

This early-phase study tests a new drug, ONM-501, injected directly into tumors, either alone or with another drug (cemiplimab), in people with advanced solid tumors or lymphomas that have not responded to other treatments. The main goals are to find the safest dose and understan…

This early-stage study tests a new drug called TJ033721 (givastomig) in people with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. About 330 partici…

This study tests a radioactive imaging agent called Y-NM600 in people with metastatic cancer who are already receiving immunotherapy (anti-PD-1 or anti-PD-L1 drugs). The goal is to find the safest dose and see if the agent can help the immunotherapy work better. Up to 60 particip…

This study tests whether combining two drugs, cabozantinib and nivolumab, can slow the growth of prostate cancer that has spread and stopped responding to hormone therapy. About 47 men will receive the treatment. The main goal is to see how long the cancer stays under control.

This study is for people with metastatic cancer that has a specific genetic change called an ATM mutation. Researchers want to see if using a lower dose of radiation can still control the tumor while causing fewer side effects. About 45 adults will receive targeted radiation and …

This study tests a new approach for people with liver metastases (cancer that has spread to the liver from another part of the body). Doctors will deliver the drug bevacizumab directly into the liver along with standard chemo during a procedure called TACE. The goal is to see if …

This study tests a new approach for people with many cancer spots (metastases). Half get standard care, the other half get precise, high-dose radiation (SABR) to every tumor. The goal is to see if this aggressive treatment improves survival and quality of life. About 138 adults w…

This study tests a new treatment for people with advanced cancers that have spread and express a protein called NY-ESO-1. Patients receive a single infusion of their own immune cells that have been genetically modified to recognize and attack cancer cells. The goal is to see if t…

This early-stage study tests a two-part approach for people with metastatic cancer. First, a special dye helps doctors see tumors on a scan. Then, a targeted treatment delivers radiation directly to those tumors. The goal is to check safety and whether the treatment can shrink or…

This early-phase study tests whether giving targeted radiation to up to 10 tumor spots can improve the effects of immunotherapy in people with advanced solid tumors that have spread to 3-10 places in the body. About 28 adults will receive the combined treatment, and researchers w…

This study tests a new drug called JZP815 in people with advanced or spreading solid tumors that have specific genetic changes in the MAPK pathway. The main goals are to find a safe dose and see if the drug can shrink tumors. About 332 adults who have tried all other standard tre…

This early-phase study tests a new treatment called PTC13, which uses a patient's own immune cells (T-cells) engineered to attack cancer cells that have a protein called CEA. The study includes adults with advanced colorectal, stomach, pancreatic, or other solid tumors that have …

This study tests whether a precise, high-dose radiation treatment can restore the cancer-fighting power of immunotherapy in people with metastatic solid tumors. Participants must have had a good initial response to immunotherapy for at least 6 months, but then their cancer starte…

This study tests a new daily pill, INX-315, in 150 people with advanced breast, ovarian, or other solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe and can shrink or control tumors. The study includes three parts: testing the…

This early-phase study tests a new drug called IPH5301 in people with advanced solid tumors that have spread. The drug aims to block a protein (CD73) that helps tumors hide from the immune system. The trial first finds the safest dose alone, then tests it with chemotherapy and an…

This study tests a radiation treatment (Y90) to help grow the liver in people with liver cancer who need surgery but don't have enough healthy liver left. The goal is to make surgery possible and improve survival. About 104 participants will receive either standard or optimized Y…

This study tests whether adding the experimental drug givastomig to standard immunotherapy and chemotherapy helps people with advanced stomach or esophageal cancer live longer without their cancer growing. About 180 adults whose tumors have certain proteins (CLDN18.2 and PD-L1) w…

This early-stage study tests a new treatment called MQ710, made from a modified virus, for people with advanced solid tumors that have not responded to standard therapies. The treatment is injected directly into tumors, either alone or with the immunotherapy drug pembrolizumab. T…

This study tests a new drug called AU-007 in people with advanced solid tumors (like melanoma or lung cancer) that cannot be removed by surgery or have spread. The drug is designed to help the immune system fight cancer more effectively. About 159 participants will receive AU-007…

This study tests a new drug, FOG-001, in about 595 people with advanced solid tumors that have not responded to other treatments. The goal is to see if FOG-001 is safe and can shrink tumors or slow their growth. The trial focuses on several cancer types, including colorectal, pro…

This phase 3 study compares a new two-drug immunotherapy (botensilimab + balstilimab) against the current standard treatment (chemotherapy plus nivolumab) in people with advanced or metastatic stomach or esophageal cancer that has a specific genetic feature (MSI-H/dMMR). The goal…

This early study tests a special radioactive tracer called [68Ga]Ga-ABY-025 for PET scans. The goal is to see if it can better find and show HER2-positive tumors in people with advanced or metastatic cancer who are already receiving standard HER2-targeted therapy. About 30 adults…

This study tests a new radioactive tracer called 68Ga-FXX489 (NNS309) that helps PET/CT scans find tumors and cancer spread. About 30 adults with suspected cancer will receive the tracer and be scanned to see how well it lights up tumors and how safe it is. The goal is to improve…

This early-phase study tests a new radioactive tracer called FAP-2286 to see how well it can find cancer that has spread in adults with solid tumors. About 191 participants will get an injection of the tracer and then have a PET scan. The goal is to measure safety and how accurat…

This early-stage study tests a new PET imaging agent, 18F-Clofarabine, to measure an enzyme (DCK) activity in metastatic cancers. The goal is to see if this scan can predict whether drugs like gemcitabine will be taken up by cancer cells. About 4 adults with metastatic cancer wil…

This study tests a special type of proton radiation called GRID to relieve symptoms from large tumors (at least 4.5 cm) that cannot be surgically removed or have spread. The treatment delivers high-dose radiation in a pattern of peaks and valleys, aiming to be effective while red…

This study tests a special type of radiation called lattice therapy for people with large, hard-to-treat tumors. The goal is to see if it can shrink tumors better and with fewer side effects than standard radiation. About 37 adults with advanced solid tumors will receive this tre…

This study tests a program called ApricityCare that helps doctors spot and treat side effects from cancer therapy early. The goal is to prevent side effects from getting worse and reduce the number of people who have to stop their cancer treatment. About 425 adults with cancer wi…

This study compares two support programs for parents with advanced cancer who want to improve communication with their children (ages 10-25). One program provides education, while the other adds hands-on practice. The goal is to help parents talk more openly and comfortably about…

This study tests a simple scoring system to predict if patients with metastatic cancer will survive at least 30 days. Researchers will assign a score based on lab results, emergency room visits, and cancer type. The goal is to help doctors and patients make better decisions about…

This study is a registry that collects information from 2000 adults with metastatic cancer who are receiving radiation therapy as part of their standard care. The goal is to gather clinical data and patient-reported outcomes to help researchers better understand how radiation the…

This study looks at whether a special shirt called Hexoskin can help track side effects in 100 people getting radiation for cancer that has spread. Participants wear the shirt and use a phone app to report symptoms. The goal is to see if this approach is practical and can catch p…

This study is for people with a certain type of advanced breast cancer (lobular) that is hormone receptor-positive. The goal is to find better ways to detect when the cancer becomes resistant to hormone therapy. Researchers will use special PET scans and blood tests to look for c…

This study looks at how much of the drug T-DXd gets into brain tumors in people with HER2-positive brain cancer or glioblastoma. About 30 adults will receive the drug before surgery, and researchers will measure drug levels in the tumor during the operation. The goal is to unders…

This study collects information from 300 adults with cancer that has spread to other parts of the body (metastatic cancer) who are receiving or have received a precise, high-dose type of radiation called ablative radiotherapy. The goal is to track short-term side effects to bette…

This study compares a newer MRI-based scan (DWI) with the standard FDG PET scan to see how well each finds cancer spread in people with metastatic cancer. About 30 adults with cancer that has spread will get both scans, and researchers will compare the results. The goal is to see…

This study looks at whether asking people with advanced or metastatic cancer about their financial worries every month can improve their quality of life and reduce stress. About 1,000 adults who are getting cancer treatment that is not meant to cure them will take part. The goal …